Ryan Long on How the 340B Drug Program Got Hijacked—and What It’s Costing Patients cover art

Ryan Long on How the 340B Drug Program Got Hijacked—and What It’s Costing Patients

Ryan Long on How the 340B Drug Program Got Hijacked—and What It’s Costing Patients

Listen for free

View show details

About this listen

 In this episode of DC EKG, policy expert Ryan Long unpacks the tangled evolution of the 340B program—from its origins in the early 1990s to its explosive, unintended role in today’s healthcare market. Originally designed to help hospitals serving the uninsured access affordable drugs, 340B has morphed into a tool for profit, driving hospital consolidation, inflating costs, and straining the biotech innovation ecosystem. Ryan explains how vague eligibility rules, lack of oversight, and policy loopholes have turned a small support program into a massive $54 billion industry—with no requirement that savings actually reach the patients it's meant to help. This is a must-listen for anyone interested in how drug pricing policy, hospital behavior, and innovation incentives are shaping the future of medicine in America.
activate_mytile_page_redirect_t1

What listeners say about Ryan Long on How the 340B Drug Program Got Hijacked—and What It’s Costing Patients

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.